Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

AstraZeneca (AZN) stock in focus as the U.S. FDA expands approval for its lymphoma therapy Calquence with chemoimmunotherapy ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...

The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...

The Food and Drug Administration has granted traditional approval to Calquence with bendamustine and Rituxan for some ...

AstraZeneca’s (AZ) Calquence (acalabrutinib) has been approved by the US Food and Drug Administration (FDA) as part of a ...

Investing.com -- AstraZeneca (LON: AZN) in a stock exchange filing on Friday said that the FDA approved its drug Calquence ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

The FDA has approved Calquence (acalabrutinib) for use in combination with bendamustine and rituximab to treat adults with previously untreated MCL who are ineligible for transplant.

AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression.

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

Calquence in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients ...